Why is it important to assess for drug interactions prior to initiating INH?

Assessing for drug interactions prior to initiating isoniazid (INH) is crucial to prevent adverse effects and ensure optimal therapeutic outcomes. INH is a primary medication used in the treatment and prevention of tuberculosis, and it can interact with several other medications. These interactions can lead to increased toxicity, reduced effectiveness of the therapies involved, or worse overall patient health outcomes.

For example, INH can interact with drugs metabolized by the liver, as it affects hepatic enzymes. If a patient is taking another medication that shares the same metabolic pathway, the risk of side effects or reduced efficacy increases. By identifying these potential drug interactions beforehand, healthcare providers can make informed decisions about alternative treatments or adjust dosages accordingly, thereby minimizing risks and maximizing the therapeutic effects of the medications involved.

This proactive approach is essential for maintaining patient safety and achieving the best possible treatment outcomes when using INH and other medications concurrently.